National-Service Continuity Board Adviser

The mandate

The committee repeatedly asks whether continuity plans preserve a complete clinical service or merely recover individual facilities. Donor availability, rare blood typing, testing, processing, cold storage, inter-island transport, specialist rosters, hospital ordering and clinical allocation have separate contingencies. Several assume the same people, fuel, communications or air capacity. Directors need an independent view of simultaneous disruption and the ethical choices that arise before national supply becomes critical.

Three days each month cover evidence review, a management challenge, chair consultation and follow-up. Six clinical-and-risk committee sessions and four collection, laboratory or hospital-interface reviews are included. The adviser will answer an urgent, bounded question about a declared national continuity threat within four hours when available; this does not create an on-call command duty, and management retains incident leadership at all times.

The term is twelve months through two national exercises and one severe-weather season. Any further appointment requires a new resolution identifying a changed continuity question, evidence that internal owners have embedded recommendations, and a refreshed conflict review. Renewal is not automatic, and a live incident near term end does not silently convert advisory influence into continuing operational responsibility.

The adviser has no line authority and carries no executive responsibility for collection, laboratory release, clinical allocation, transport, technology, workforce, emergency declaration or hospital communication. Accountable executives and clinicians own service decisions; the board governs appetite. The adviser may challenge compound assumptions and ethical preparedness but cannot release product, ration supply, direct staff or speak for the national service.

Current work for blood-product suppliers, laboratories, logistics providers, hospitals, health-technology vendors, unions, emergency agencies or competing clinical services must be disclosed. A relevant commercial or governance interest requires issue-level recusal. Fees cannot depend on supplier selection, inventory held, exercises passed or later implementation, and no paid referral or product endorsement is permitted.

Why the board wants this voice

Functional plans are professionally owned and independently assured, but their shared assumptions are visible only when a national exercise forces simultaneous failure. Few directors have commanded a perishable clinical supply network through infrastructure disruption. The board needs experienced challenge that connects ethical allocation and physical recovery while leaving every clinical and executive duty intact.

What you will own

• Press management to define protected clinical outcomes, minimum service states, decision clocks and recovery priorities by disruption class.
• Test donor, laboratory, cold-chain, transport, specialist-workforce, digital and hospital contingencies for shared hidden dependencies.
• Challenge inventory comfort that ignores product mix, expiry, location, testing status, clinical substitution and transport accessibility.
• Probe how ethical allocation, clinical authority, hospital communication and public messaging would operate before scarcity becomes acute.
• Observe two exercises and identify invented capacity, duplicated people, unavailable evidence, slow authority and unsafe restoration assumptions.
• Shape board conditions for resilience investment, mutual aid, workforce cross-credentialing and periodic contingency retirement.
• Give the chair an end-to-end vulnerability map, exercise findings, conflict record and questions for annual assurance.

Candidate qualifications

• Led blood, transplant, pharmaceutical or other perishable clinical-supply operations during material national disruption.
• Understands donor or source availability, laboratory release, cold chain, scarce specialist rosters and clinical allocation together.
• Has exposed contingencies that independently passed review but relied on the same unavailable people, transport or infrastructure.
• Can challenge ethical scarcity preparation without taking clinical authority or presuming a single acceptable allocation policy.
• Advised public-service boards while respecting emergency agency, hospital, regulator and accountable-executive boundaries.
• Maintained independence from clinical suppliers, logistics providers, laboratories, technology vendors and affected institutions.

Non-negotiables

• Can attend six Wellington committee sessions, four interface reviews and both national exercises during the term.
• Will disclose clinical-provider, supplier, laboratory, logistics, union and emergency-agency relationships before appointment.
• Brings real perishable clinical-network disruption experience; continuity-plan review alone is insufficient.
• Accepts no collection, laboratory, clinical, allocation, incident, transport, workforce or board-voting authority.

1. 49 words maximum. Describe two clinical continuity plans that failed together because they shared one hidden dependency.
2. 49 words maximum. Which provider, supplier or public-service relationship could require your recusal?
3. 49 words maximum. What evidence would tell a board that national blood inventory is not practically accessible?